Germany
Spain
Japan
United States
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy
Published by:
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim / Rhein, Germany
Trade Register of the Local Court of Mainz, HRB 21005
Identification number for turnover tax: DE 81 11 37 994
Board of Managing Directors:
Hubertus von Baumbach
Dr. Joachim Hasenmaier
Allan Hillgrove
Simone Menne
Dr. Andreas Neumann
Dr. Michel Pairet
Chairman of the Shareholders' Committee
Christian Boehringer
Phone: +49-6132-77-0
Fax: +49-6132-72-0
E-Mail: For queries please write to press@boehringer-ingelheim.com